Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157691 | 0.98 | CA1 (0.55) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL21202659 | 0.82 | CA1 (0.51) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL8359924 | 0.81 | RAPGEF4 (0.47) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL13831247 | 0.79 | NOX1 (0.50) | LMNAHTTSMN1; SMN2GAARAB9A | |
| SCHEMBL8362209 | 0.79 | RAB9A (0.44) | LMNAHTTSMN1; SMN2GAARAB9A | |
| SCHEMBL14272821 | 0.78 | NR4A2 (0.42) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL8776014 | 0.78 | CYP3A4 (0.47) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL14364963 | 0.78 | MEN1 (0.42) | CA1CA14LMNAHTTTP53 | |
| SCHEMBL25786554 | 0.78 | KMT2A (0.40) | GAANR4A2 | |
| SCHEMBL14407222 | 0.78 | ADRA2A (0.43) | CA1CA14LMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1904435-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. | 2010-03-18 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1904435-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | Amgen Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006138508-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | CA1 4170/4885CA14 3626/4885LMNA 2209/4885 |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | GPR119, GLP1R, UGT2B7 | CA1 4170/4885CA14 3626/4885LMNA 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.